Maria Elena Bottazzi | Co-Director of Texas Children's Hospital Center for Vaccine Development
Baylor College of Medicine

Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine

Maria Elena Bottazzi, PhD is an internationally recognized vaccinologist and global health leader advancing scalable vaccine innovations for neglected tropical diseases and emerging infections. She serves as Senior Associate Dean of the National School of Tropical Medicine at Baylor College of Medicine and Co‑Director of the Texas Children’s Hospital Center for Vaccine Development. Dr. Bottazzi has built end‑to‑end vaccine development pipelines that move technologies from discovery through clinical development using sustainable product development partnerships. Her work focuses on developing accessible, affordable vaccines for populations in low‑ and middle‑income countries, with an emphasis on platform technologies, manufacturability, and global deployment. She is a pioneer in equitable vaccine innovation and was part of the team that developed an open‑science COVID‑19 vaccine technology designed for global manufacturing without intellectual property barriers. Her work has contributed to advancing multiple vaccine candidates into clinical trials across diverse global settings. Elected to the U.S. National Academy of Medicine in 2024, Dr. Bottazzi is widely recognized for combining scientific innovation with policy, partnerships, and global access strategies. Her leadership exemplifies a model of vaccine development that integrates science, translation, and international collaboration to address some of the world’s most pressing infectious disease challenges.

Appearances:



Day 1 (20th October) @ 10:15

One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime

  • How can combination vaccines support life-course immunisation strategies and close immunity gaps at every age? 
  • Could combining priority pathogens in a single shot improve vaccine coverage, or will it introduce new barriers for uptake and delivery? 
  • What is the economic value of combination vaccines? 
  • What standards do we need to ensure multi-antigen vaccines perform consistently without compromising safety or effectiveness? 
  • What strategies can we use to ensure broad accessibility of combination vaccines, including considerations around technology, adjuvants, and formulation? 
  • Which pairings have the strongest potential to reduce global disease burden, especially in regions with limited resources? 

Day 1 (20th October) @ 16:00

Panel: Expanding the Access & Impact of Adjuvants

  • How can we overcome IP and licensing challenges to make novel adjuvants more globally accessible?   
  • How can regulators harmonize approval pathways for adjuvanted vaccines without compromising safety or slowing innovation?   
  • How can collaboration between academia, industry, and funders, accelerate development and equitable distribution of new adjuvants?   
  • What emerging adjuvant platforms or innovative technologies are available that could transform next-generation vaccines, and what obstacles exist to their deployment?   
Session led by: Croda Inc

Day 2 (21st October) @ 14:45

Update on Hookworm Vaccine Initiative

last published: 05/Aug/26 16:17 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2026

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com


Stan Dooley

Stan.Dooley@terrapinn.com

 

TO SPEAK


Isla Sutherland

Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com